Literature DB >> 18319419

Adjuvant therapy for surgically resected pancreatic adenocarcinoma.

James L Abbruzzese.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18319419     DOI： 10.1001/jama.299.9.1066

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  10 in total

Review 1.  Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?

Authors:  Ruchika Gutt; Stanley L Liauw; Ralph R Weichselbaum
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-11-25

2.  Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.

Authors:  Jin-Hyeok Hwang; Johannes Voortman; Elisa Giovannetti; Seth M Steinberg; Leticia G Leon; Yong-Tae Kim; Niccola Funel; Joo Kyung Park; Min A Kim; Gyeong Hoon Kang; Sun-Whe Kim; Marco Del Chiaro; Godefridus J Peters; Giuseppe Giaccone
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

3.  Repeated Pancreatectomy for Recurrent Pancreatic Carcinoma after Pylorus-Preserving Pancreatoduodenectomy: Report of Two Patients.

Authors:  Toshitatsu Ogino; Junji Ueda; Norihiro Sato; Shunichi Takahata; Kazuhiro Mizumoto; Masafumi Nakamura; Yoshinao Oda; Masao Tanaka
Journal:  Case Rep Gastroenterol       Date:  2010-10-09

4.  Severe eosinophilic pneumonia presenting during gemcitabine adjuvant chemotherapy.

Authors:  Tomomi Yakabe; Kenji Kitahara; Kazutoshi Komiya; Naoko Sueoka-Aragane; Shinya Kimura; Takashi Sugioka; Hirokazu Noshiro
Journal:  World J Surg Oncol       Date:  2013-07-24       Impact factor: 2.754

5.  Peptidylarginine Deiminase Inhibitor Application, Using Cl-Amidine, PAD2, PAD3 and PAD4 Isozyme-Specific Inhibitors in Pancreatic Cancer Cells, Reveals Roles for PAD2 and PAD3 in Cancer Invasion and Modulation of Extracellular Vesicle Signatures.

Authors:  Pinar Uysal-Onganer; Stefania D'Alessio; Maria Mortoglou; Igor Kraev; Sigrun Lange
Journal:  Int J Mol Sci       Date:  2021-01-30       Impact factor: 5.923

6.  Role of microRNAs in response to cadmium chloride in pancreatic ductal adenocarcinoma.

Authors:  Maria Mortoglou; Aleksandra Buha Djordjevic; Vladimir Djordjevic; Hunter Collins; Lauren York; Katherine Mani; Elizabeth Valle; David Wallace; Pinar Uysal-Onganer
Journal:  Arch Toxicol       Date:  2021-12-14       Impact factor: 5.153

7.  Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth.

Authors:  S J Deharvengt; J R Gunn; S B Pickett; M Korc
Journal:  Cancer Gene Ther       Date:  2009-10-23       Impact factor: 5.987

8.  PV1 down-regulation via shRNA inhibits the growth of pancreatic adenocarcinoma xenografts.

Authors:  Sophie J Deharvengt; Dan Tse; Olga Sideleva; Caitlin McGarry; Jason R Gunn; Daniel S Longnecker; Catherine Carriere; Radu V Stan
Journal:  J Cell Mol Med       Date:  2012-11       Impact factor: 5.310

9.  High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer.

Authors:  Elisa Giovannetti; Arjan van der Velde; Niccola Funel; Enrico Vasile; Vittorio Perrone; Leticia G Leon; Nelide De Lio; Amir Avan; Sara Caponi; Luca E Pollina; Valentina Gallá; Hiroko Sudo; Alfredo Falcone; Daniela Campani; Ugo Boggi; Godefridus J Peters
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

Review 10.  Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.

Authors:  Marwan Al-Hajeili; Asfar S Azmi; Minsig Choi
Journal:  Onco Targets Ther       Date:  2014-02-04       Impact factor: 4.147
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.